Neuroimaging Modalities Used for Ischemic Stroke Diagnosis and Monitoring

Nukovic, Jasmin J.; Opancina, Valentina; Ciceri, Elisa; Muto, Mario; Zdravkovic, Nebojsa; Altin, Ahmet; Altaysoy, Pelin; Kastelic, Rebeka; Velazquez Mendivil, Diana Maria; Nukovic, Jusuf A.; Markovic, Nenad V.; Opancina, Miljan; Prodanovic, Tijana; Nukovic, Merisa; Kostic, Jelena; Prodanovic, Nikola

doi:10.3390/medicina59111908

Cited by 8 publications

(1 citation statement)

References 67 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Magnetic resonance imaging (MRI) is more sensitive but has many limitations: it cannot be performed on patients with pacemakers and other metal objects, as well as in anxious patients. It is also less accessible, more time-consuming, and generates higher costs [6][7][8]. The commonly used National Institutes of Health Stroke Scale (NIHSS) was designed to determine the physical size of the ischemic area.…”

Section: Introductionmentioning

confidence: 99%

Predicting Short- and Long-Term Functional Outcomes Based on Serum S100B Protein Levels in Patients with Ischemic Stroke

Jalali,

Zwiernik,

Rotkiewicz

et al. 2024

JPM

View full text Add to dashboard Cite

Background: Ischemic stroke is one of the leading causes of mortality and disability. The neuroimaging methods are the gold standard for diagnostics. Biomarkers of cerebral ischemia are considered to be potentially helpful in the determination of the etiology and prognosis of patients with ischemic stroke. Aim: This study aimed to investigate the usefulness of serum S100B protein levels as a short- and long-term prognostic factor in patients with ischemic stroke. Study design and methods: The study group comprised 65 patients with ischemic stroke. S100B protein levels were measured by immunoenzymatic assay. Short-term functional outcome was determined by the NIHSS score on day 1 and the difference in the NIHSS scores between day 1 and day 9 (delta NIHSS). Long-term outcome was assessed by the modified Rankin Scale (MRS) at 3 months after the stroke. At the end of the study, patients were divided into groups based on the NIHSS score on day 9 (0–8 “good” and >8 “poor”), the delta NIHSS (“no improvement” ≤0 and >0 “improvement”), and the MRS (“good” 0–2 and >2 “poor”). Differences in S100B levels between groups were analyzed with the ROC curve to establish the optimal cut-off point for S100B. The odds ratio was calculated to determine the strength of association. Correlations between S100B levels at three time points and these variables were evaluated. Results: We revealed a statistically significant correlation between S100B levels at each measurement point (<24 h, 24–48 H, 48–72 h) and the NIHSS score on day 9 (R Spearman 0.534, 0.631, and 0.517, respectively) and the MRS score after 3 months (R Spearman 0.620, 0.657, and 0.617, respectively). No statistically significant correlation was found between S100B levels and the delta NIHSS. Analysis of the ROC curve confirmed a high sensitivity and specificity for S100B. The calculated AUC for the NIHSS on day 9 were 90.2%, 95.0%, and 82.2%, respectively, and for the MRS, 83.5%, 83.4%, and 84.0%, respectively. After determining the S100B cut-off, the odds ratio for beneficial effect (NIHSS ≤ 8 at day 9 or MRS 0–2 after 3 months) was determined for each sampling point. Conclusion: S100B is a useful marker for predicting short- and long-term functional outcomes in patients with ischemic stroke.

show abstract

Section: Introductionmentioning

confidence: 99%

Predicting Short- and Long-Term Functional Outcomes Based on Serum S100B Protein Levels in Patients with Ischemic Stroke

Jalali,

Zwiernik,

Rotkiewicz

et al. 2024

JPM

View full text Add to dashboard Cite

show abstract

Decreased Astrocytic CCL5 by MiR-324-5p Ameliorates Ischemic Stroke Injury via CCR5/ERK/CREB Pathway

Li,

Gao,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Following ischemic stroke, Ccl5 mRNA expression increased, while miR-324-5p expression decreased in the peri-infract cortex of middle cerebral artery occlusion (MCAO) mice. However, the roles of CCL5 and miR-324-5p in stroke remain unclear. Here, we show that inhibiting CCL5 using antibodies or miR-324-5p not only reduced infarct area and preserved neurological function in MCAO mice but also attenuated astrocyte and microglia activation, protected dendritic structures, and maintained spine density. In an astrocyte-neuron co-culture system after oxygen-glucose deprivation (OGD), knockdown astrocytic CCL5 expression by antibody or miR-324-5p decreased neuronal apoptosis and preserved dendritic architecture. Importantly, the suppression of CCL5 enhanced the activation of the ERK/CREB pathway both in vivo and in vitro. Consistent with these findings, the application of Maraviroc, a CCR5 antagonist, reduced infarct size, decreased neuronal apoptosis, and upregulated the ERK/CREB pathway in neurons treated with OGD. In conclusion, targeting the CCL5 pathway via miR-324-5p represents a promising therapeutic strategy for alleviating ischemic stroke damage through modulation of neuronal CCR5/ERK/CREB pathway.

show abstract

Predictors of anxiety in patients undergoing magnetic resonance imaging scans: a multicenter cross-sectional study

Masalma,

Zidan,

Amasheh

et al. 2024

BMC Psychiatry

View full text Add to dashboard Cite

Neuroimaging Modalities Used for Ischemic Stroke Diagnosis and Monitoring

Cited by 8 publications

References 67 publications

Predicting Short- and Long-Term Functional Outcomes Based on Serum S100B Protein Levels in Patients with Ischemic Stroke

Predicting Short- and Long-Term Functional Outcomes Based on Serum S100B Protein Levels in Patients with Ischemic Stroke

Decreased Astrocytic CCL5 by MiR-324-5p Ameliorates Ischemic Stroke Injury via CCR5/ERK/CREB Pathway

Predictors of anxiety in patients undergoing magnetic resonance imaging scans: a multicenter cross-sectional study

Contact Info

Product

Resources

About